UCI MD/PhD student Casey Vanderlip has been selected as one of six early-career researchers featured in the 2026 international Clinical Trials on Alzheimer’s Disease (CTAD) Rising Stars Showcase.
The annual showcase, presented in partnership with the Alzheimer’s Association, recognizes emerging investigators whose work is helping advance Alzheimer’s disease clinical research. Casey will present his research at the CTAD conference in Boston on November 18.
Casey has been a highly productive student at UC Irvine. He won the UCI Grad Slam competition in 2025 and was selected for the 2026 UCI Lauds and Laurels Outstanding Graduate Student Award. These honors highlight his promise as a future research leader and UCI MIND’s commitment to preparing the next generation of Alzheimer’s researchers.
Searching for subtle changes before symptoms appear
Casey’s research examines whether brief digital memory assessments can help researchers detect subtle cognitive changes associated with the earliest biological stages of Alzheimer’s disease.
His CTAD presentation, “Digital Cognitive Signatures of Biomarker-Defined Preclinical Alzheimer’s Disease,” draws on screening information from two large Alzheimer’s prevention trials, AHEAD and A4.
Preclinical Alzheimer’s disease refers to a period when biological changes associated with Alzheimer’s are present in the brain, but noticeable problems with memory and thinking have not yet developed. This stage is especially important to researchers studying whether treatments may be able to delay or prevent symptoms.
The research suggests that digital memory assessments may be sensitive to biologically meaningful cognitive changes, particularly in people with evidence of both amyloid and tau accumulation.
These assessments are not intended to diagnose Alzheimer’s disease on their own. Instead, they may eventually offer researchers a scalable and less burdensome way to identify potential participants, monitor change and improve the design of prevention and early-intervention trials.
Improving the way prevention trials are conducted
Alzheimer’s prevention trials face a difficult challenge: Researchers must identify people who do not have noticeable symptoms but may be at increased risk of developing them in the future.
Brain imaging and blood-based biomarkers can help researchers understand the biological changes taking place. Casey’s work indicates that digital cognitive assessments may provide complementary information about whether those changes are beginning to affect specific types of memory.
More sensitive assessments could also help researchers select participants who are appropriate for a particular study and measure whether an experimental treatment is having its intended effect. Improving these processes may allow clinical trials to reach reliable answers more efficiently.
The findings Casey will present at CTAD remain research results. Additional study will be needed before digital assessments of this kind could be considered for broader clinical use.
Developing accessible tools for Alzheimer’s research
Casey conducts his research in the laboratory of Craig Stark, PhD, at UC Irvine. His work focuses on the hippocampus and surrounding areas of the brain that play a central role in memory and are affected by aging and Alzheimer’s disease.
By combining digital memory assessments with brain imaging and blood-based biomarkers, he aims to develop tools that can help researchers detect change earlier, predict future decline and improve the recruitment and monitoring of clinical-trial participants.
Since joining the Stark Lab, Casey has established an exceptional record of scholarship. During three years in the lab while pursuing his doctorate, he has published 14 first-author papers and 20 papers overall.
Training the next generation
Moving Alzheimer’s research forward will require new treatments and diagnostic tools, as well as researchers trained to bring discoveries from the laboratory into carefully designed human studies.
UCI MIND provides students and early-career investigators with opportunities to work across disciplines, learn from experienced Alzheimer’s researchers and contribute to large collaborative studies.
Casey’s recognitions reflect the importance of investing in the next generation of clinicians and scientists—and the innovative work already underway at UC Irvine to improve how Alzheimer’s disease is studied.
Learn more about Casey Vanderlip’s research and explore current UCI MIND research studies and clinical trials.
